The Program in Personalized Medicine & Targeted Therapeutics and Mayes College of Healthcare Business and Policy present Making the Connections: Personalized Medicine—From Promise to Public Health and Policy.
Advances in fields such as genetics and genomics have created new opportunities for personalized medicine applications in clinical practice and health care delivery. This conference, featuring a panel of renowned speakers, will provide an engaging update of the field of personalized medicine and explore the field from public health and health policy perspectives as well as business and economic aspects.
Tuesday, April 17, 2012, from 5:30 to 7:30 p.m.
University of the Sciences
McNeil Science and Technology Center
AstraZeneca Auditorium
45th Street at Woodland Avenue
Philadelphia, Pa. 19104
Click here to register online.
For more information, e-mail MayesCollegeConnections@usciences.edu or call 866.431.0845.
Made possible by an unrestricted educational grant from AstraZeneca Pharmaceuticals.
 |
Add to Apple iCal |
 |
Add to Outlook |
 |
Add to Google Calendar |
Speakers
Stephen Kimmel, MD, MSCE
Professor of Medicine and Professor of Epidemiology
University of Pennsylvania Perelman School of Medicine
"Personalized Medicine: The Promise and the State of the Science"
Dr. Stephen Kimmel’s research focuses on interventions to improve medical treatments, including adherence and pharmacogenetic interventions. He is currently principal investigator on a number of grants evaluating cardiac medications, including a study examining the relationship between myocardial infarction and use of nonsteroidal anti-inflammatory drugs and a study examining the effects of genetic polymorphisms and patient adherence on anticoagulation control. Dr. Kimmel is professor of medicine in the Cardiovascular Division, professor of epidemiology in the Department of Biostatistics and Epidemiology, and deputy director of the Clinical Epidemiology Unit of the Center for Clinical Epidemiology and Biostatistics, and deputy director of the Epidemiology Division of the Department of Biostatistics and Epidemiology at the University of Pennsylvania's Perelman School of Medicine. He is also the founding director of the Center for Therapeutic Research in the School of Medicine. He received his AB from Princeton University, his MD from New York University School of Medicine, and a master of science in clinical epidemiology from the University of Pennsylvania School of Medicine.
Michael F Christman, PhD
President and CEO
Coriell Institute for Medical Research
"Measuring the Value of Personalized Medicine: Economic and Business Perspectives"
Dr. Michael Christman is president and chief executive officer of the Coriell Institute for Medical Research. Dr. Christman is an expert in genetics and genomics, with a focus on the integration of genome information into the delivery of clinical care. In 2007, Dr. Christman initiated the Coriell Personalized Medicine Collaborative® (CPMC®), a research study evaluating the utility of using the knowledge of genetics in medicine. The CPMC project involves more than 5,000 participants in 47 states, four hospital partners, and numerous academic collaborators. As a leader in the exploration of genomics, Coriell is paving the way toward the development of personalized medicine.
Prior to joining Coriell, Dr. Christman served as professor and founding chair of the Department of Genetics and Genomics for Boston University School of Medicine. There he led an international team of scientists in one of the first genome-wide association studies using the Framingham Heart Study cohort, published in Science magazine in 2006. Dr. Christman received his bachelor’s degree in chemistry with honors from the University of North Carolina, Chapel Hill, his doctorate in biochemistry from the University of California, Berkeley, and was a Jane Coffin Childs postdoctoral fellow at the Massachusetts Institute of Technology.
Amalia M. Issa, PhD, MPH
Professor and Chair
Department of Health Policy and Public Health
Director, Program in Personalized Medicine & Targeted Therapeutics
University of the Sciences
"Enabling the Future of Healthcare: Public Health and Policy Issues in Personalized Medicine"
Dr. Amalia M. Issa, is internationally recognized in the field of personalized medicine and founded the Program in Personalized Medicine and Targeted Therapeutics in 2001 as one of the first centers focused on pharmacogenomics and personalized medicine to advance the science and translation of personalized medicine through state-of-the-art research and education. Dr. Issa developed a unique area of translational research focused on pharmacogenomics and personalized medicine applications, and how they will be translated and integrated into health care delivery and health systems. Her research is positioned at the nexus of epidemiology/health services research and molecular science, and she leads an interdisciplinary team of scientists who are actively engaged in research aimed at the effective translation of the science of pharmacogenomics and personalized medicine from the laboratory bench to the bedside and to the community and policy.
Dr. Issa has served or is serving as the principal investigator on a number of funded projects, and is a reviewer for several scientific journals and granting agencies. She serves on editorial boards and in leadership positions in several professional associations, and has received many awards and honors for her work. She holds degrees from Concordia University (bachelor of science in biology), McGill University (PhD in neuropharmacology from the Department of Neurology and Neurosurgery), an MPH from the UCLA School of Public Health, and completed fellowship training at Harvard Medical School.
Moderator:
George E. Downs, PharmD
Dean Emeritus, Philadelphia College of Pharmacy (PCP) at USciences, and professor of clinical pharmacy
Dr. George E. Downs has been a faculty member at USciences since 1972, including dean of PCP from 1995 to 2004 when he oversaw the transition to a doctor of pharmacy accelerated program. Dr. Downs is a fellow of the College of Physicians of Philadelphia and president of the Health Promotion Council of Southeastern Pennsylvania. He graduated from the University of New Mexico College of Pharmacy with a BS in pharmacy and earned his PharmD degree at PCP.
Continuing Education
Making the Connections: Personalized Medicine—From Promise to Public Health and Policy is a knowledge-based, CPE activity. In order to obtain credit attendees must participate in the entire program and complete the online evaluation and learning assessment with a score of 70% or higher.
Objectives:
- Describe at least two recent example of development in cardiovascular pharmacogenomics/personalized medicine.
- Define pharmacogenomics and personalized medicine and provide examples of clinical utility.
- Articulate the most recent FDA regulatory actions related to pharmacogenomics and personalized medicine.
- Describe some examples of the economic implications of personalized medicine for health care.
- Name 3-5 ways that the integration of personalized medicine approaches in clinical care changes clinical practice, including specifically for pharmacists.
The Philadelphia College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program (0056-9999-12-057-L04-P) is acceptable for 2 contact hours of continuing education credit in states that recognize ACPE approved providers. In order to receive credit, you must complete the online evaluation and learning assessment with a score of 70% or higher.
About (P2MT2)TM and Mayes
Program in Personalized Medicine & Targeted Therapeutics
The Program in Personalized Medicine & Targeted Therapeutics (P2MT2)TM was founded in 2001 as one of the first centers focused on pharmacogenomics and personalized medicine by Dr. Amalia Issa to advance the science and translation of personalized medicine through state-of-the-art research and education and moved to USciences in 2011. They are a multidisciplinary group of faculty, staff, students, fellows and collaborators who conduct research aimed at understanding how personalized medicine applications will be translated from bench to bedside to community and integrated effectively into clinical practice and health care delivery.
Mayes College of Healthcare Business and Policy
Healthcare and pharmaceutical spending is more than 1/6 of the US economy. Mayes College of Healthcare Business and Policy, located in the center of the Northeast pharmaceutical corridor, educates the people who keep the healthcare industry moving. Business leaders, policy makers, researchers, and healthcare writers learn how to have a positive impact on the business of healthcare at Mayes.
Mayes provides education in specialized fields like Biomedical Writing, Pharmaceutical and Healthcare Business, Health Policy and Public Health, and provides students with hands-on learning experiences, internships, and personal connections. This gives our graduates a leg up on the competition when it comes to career prospects in healthcare industries.